Compass’ Bispecific BTC Contender Meets Phase II/III Endpoint

But Additional Survival Data Awaited

 
• By Jung Won Shin
  
clinical trials
Meeting Secondary Endpoints Will Increase Confidence In Tovecimig (Shutterstock)

More from South Korea

More from R&D